Neuraxpharm Snapped Up By Private Equity In Europe’s Largest Deal
Under Control Of Apax Partners Since 2016
Created in 2016 by consolidating five European companies, CNS specialist Neuraxpharm is changing hands, with funds advised by global investor Permira paying an undisclosed sum to take control of a business boasting annual revenues of around €460m ($541m) and more than 115 CNS molecules at its disposal.
You may also be interested in...
Following a strategic review, AMAG goes to Covis. Vincera goes public in merger with blank check company, has pending cancer deal with Bayer.
Neuraxpharm says a deal with Takeda to acquire the only buccal midazolam approved across Europe, Buccolam, not only gives the CNS specialist a strong asset but also offers the opportunity to expand its commercial footprint into the Nordics and Ireland.
Perrigo’s ambitions to become a consumer-focused company are a step closer after the firm announced an immediate sale of a ‘non-core’ asset.